During the past decade, Illinois Cancer Specialists-Niles conducted 49 clinical trials. In the 10-year time frame, 49 clinical trials started and 118 clinical trials were completed, i.e. on average, 240.8% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 55 clinical trials were completed. i.e. 392.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Illinois Cancer Specialists-Niles" #1 sponsor was "National Cancer Institute (NCI)" with 44 trials, followed by "SWOG Cancer Research Network" with 16 trials sponsored, "Eastern Cooperative Oncology Group" with 15 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 13 trials sponsored and "Celgene" with 13 trials sponsored. Other sponsors include 84 different institutions and companies that sponsored additional 54 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Illinois Cancer Specialists-Niles" #1 collaborator was "National Cancer Institute (NCI)" with 51 trials as a collaborator, "Cancer and Leukemia Group B" with 9 trials as a collaborator, "NCIC Clinical Trials Group" with 8 trials as a collaborator, "SWOG Cancer Research Network" with 8 trials as a collaborator and "Bristol-Myers Squibb" with 4 trials as a collaborator. Other collaborators include 41 different institutions and companies that were collaborators in the rest 36 trials.

According to Clinical.Site data, the most researched conditions in "Illinois Cancer Specialists-Niles" are "Breast Cancer" (15 trials), "Multiple Myeloma" (9 trials), "Lymphoma" (8 trials), "Prostate Cancer" (7 trials) and "Colorectal Cancer" (6 trials). Many other conditions were trialed in "Illinois Cancer Specialists-Niles" in a lesser frequency.

Most popular intervention types in "Illinois Cancer Specialists-Niles" are "Drug" (165 trials), "Biological" (58 trials), "Other" (56 trials), "Procedure" (14 trials) and "Radiation" (12 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (37 trials), "Docetaxel" (18 trials), "Bevacizumab" (16 trials), "Rituximab" (15 trials) and "Cyclophosphamide" (14 trials). Other intervention names were less common.

The vast majority of trials in "Illinois Cancer Specialists-Niles" are 162 trials for "All" genders, 15 trials for "Female" genders and 10 trials for "Male" genders.

Currently, there are NaN active trials in "Illinois Cancer Specialists-Niles". undefined are not yet recruiting, 13 are recruiting, 49 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 98 completed trials in Illinois Cancer Specialists-Niles, undefined suspended trials, and 22 terminated clinical trials to date.

Out of the total trials that were conducted in Illinois Cancer Specialists-Niles, 11 "Phase 1" clinical trials were conducted, 85 "Phase 2" clinical trials and 91 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 1 trials that are defined as “Not Applicable".